{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:59:28Z","timestamp":1793336368238,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ejmech.2020.112235","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T12:58:07Z","timestamp":1584363487000},"page":"112235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification"],"prefix":"10.1016","volume":"193","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112235_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/cbdd.13445","article-title":"Computational methods and tools to predict cytochrome P450 metabolism for drug discovery","volume":"93","author":"Tyzack","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112235_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.pharep.2019.04.011","article-title":"Dietary lipids and environmental xenobiotics as risk factors for prostate cancer: the role of cytochrome P450","volume":"71","author":"Maksymchuk","year":"2019","journal-title":"Pharmacol. Rep. : PR"},{"key":"10.1016\/j.ejmech.2020.112235_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2004.10.007","article-title":"Cytochrome P450-mediated metabolism of estrogens and its regulation in human","volume":"227","author":"Tsuchiya","year":"2005","journal-title":"Canc. Lett."},{"key":"10.1016\/j.ejmech.2020.112235_bib4","first-page":"3026","article-title":"Tumor-specific expression of cytochrome P450 CYP1B1","volume":"57","author":"Murray","year":"1997","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112235_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151598","article-title":"CYP1B1 enhances cell proliferation and metastasis through induction of EMT and activation of wnt\/beta-catenin signaling via Sp1 upregulation","volume":"11","author":"Kwon","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112235_bib6","first-page":"10901","article-title":"Design, synthesis, and biological evaluation of cytochrome P450 1B1 targeted molecular imaging probes for colorectal tumor","volume":"61","author":"Meng","year":"2018","journal-title":"Detection"},{"key":"10.1016\/j.ejmech.2020.112235_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3892\/ijmm.2014.2041","article-title":"CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in\u00a0vivo and in\u00a0vitro","volume":"35","author":"Zhu","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2020.112235_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2017.04.042","article-title":"Inhibitors of cytochrome P450 (CYP) 1B1","volume":"135","author":"Dutour","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib9","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1021\/acs.jmedchem.5b00265","article-title":"Design and synthesis of new alpha-naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression","volume":"58","author":"Cui","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib10","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1016\/j.bmcl.2016.09.046","article-title":"Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives","volume":"26","author":"Poirier","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112235_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejmech.2017.02.016","article-title":"Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: overcoming cisplatin resistance in CYP1B1-overexpressing lines","volume":"129","author":"Horley","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112235_bib13","doi-asserted-by":"crossref","first-page":"111715","DOI":"10.1016\/j.ejmech.2019.111715","article-title":"A\u00a0drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine","volume":"183","author":"Catalano","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejmech.2019.07.030","article-title":"Repurposing mosloflavone\/5,6,7-trimethoxyflavone-resveratrol hybrids: discovery of novel p38-alpha MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators","volume":"180","author":"Hassan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ejmech.2016.07.009","article-title":"Repurposing of a drug scaffold: identification of novel sila analogues of rimonabant as potent antitubercular agents","volume":"122","author":"Ramesh","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ejmech.2017.11.101","article-title":"Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing","volume":"143","author":"Wu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.112235_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1021\/acs.jcim.8b00582","article-title":"Converging a knowledge-based scoring function: DrugScore(2018)","volume":"59","author":"Dittrich","year":"2019","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2020.112235_bib19","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2174\/1568026619666190816101948","article-title":"Virtual screening techniques in drug discovery: review and recent applications","volume":"19","author":"da Silva Rocha","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib20","series-title":"The Light and Dark Sides of Virtual Screening: what Is There to Know?","first-page":"20","author":"Gimeno","year":"2019"},{"key":"10.1016\/j.ejmech.2020.112235_bib21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1021\/acs.jcim.7b00095","article-title":"Identification of potent and selective CYP1A1 inhibitors via combined ligand and structure-based virtual screening and their in\u00a0vitro validation in sacchrosomes and live human cells","volume":"57","author":"Joshi","year":"2017","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2020.112235_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ejmech.2017.02.057","article-title":"Identification of dibenzyl imidazolidine and triazole acetamide derivatives through virtual screening targeting amyloid beta aggregation and neurotoxicity in PC12 cells","volume":"130","author":"Das","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejmech.2016.09.042","article-title":"Identification of novel microsomal prostaglandin E2 synthase-1 (mPGES-1) lead inhibitors from Fragment Virtual Screening","volume":"125","author":"Lauro","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmech.2018.05.035","article-title":"Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays","volume":"155","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/molecules18010877","article-title":"Synthesis, crystal structure, vibration spectral, and DFT studies of 4-aminoantipyrine and its derivatives","volume":"18","author":"Li","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2020.112235_bib26","doi-asserted-by":"crossref","first-page":"113733","DOI":"10.1016\/j.bcp.2019.113733","article-title":"Overcoming Taxol-resistance in A549 cells: a comprehensive strategy of targeting P-gp transporter, AKT\/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin","volume":"171","author":"Lin","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112235_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-2952(01)00643-8","article-title":"Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance","volume":"62","author":"McFadyen","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112235_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/15287394.2018.1440186","article-title":"Cytochrome P450 1B1 promotes cancer cell survival via specificity protein 1 (Sp1)-mediated suppression of death receptor 4","volume":"81","author":"Kwon","year":"2018","journal-title":"J.\u00a0Toxicol. Environ. Health Part A"},{"key":"10.1016\/j.ejmech.2020.112235_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bmc.2018.11.045","article-title":"Design and synthesis of selective CYP1B1 inhibitor via dearomatization of \u03b1-naphthoflavone","volume":"27","author":"Kubo","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib30","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib31","first-page":"1863","volume":"vol. 15","author":"Roos","year":"2019"},{"key":"10.1016\/j.ejmech.2020.112235_bib32","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib33","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/jcc.23637","article-title":"Pairwise decomposition of an MMGBSA energy function for computational protein design","volume":"35","author":"Gaillard","year":"2014","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib34","doi-asserted-by":"crossref","first-page":"9229","DOI":"10.1021\/acs.jmedchem.8b00907","article-title":"Targeting cytochrome P450 (CYP) 1B1 enzyme with four series of A-ring substituted estrane derivatives: design, synthesis, inhibitory activity, and selectivity","volume":"61","author":"Dutour","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib35","series-title":"SC 2006 Conference, Proceedings of the ACM\/IEEE","article-title":"Scalable algorithms for molecular dynamics simulations on commodity clusters","author":"Bowers","year":"2006"},{"key":"10.1016\/j.ejmech.2020.112235_bib36","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/jcc.20292","article-title":"Integrated modeling program, applied chemical theory (IMPACT)","volume":"26","author":"Banks","year":"2005","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib37","unstructured":"M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr, J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, USA, 2009."},{"key":"10.1016\/j.ejmech.2020.112235_bib38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2012","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.112235_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095716","article-title":"miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression","volume":"9","author":"Chatterjee","year":"2014","journal-title":"PloS One"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420302026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420302026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:09:16Z","timestamp":1759327756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420302026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":39,"alternative-id":["S0223523420302026"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112235","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112235"}}